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Abstract 
Purpose: We aimed to assess osteoclastogenic potential of peripheral blood mononuclear cells (PBMC) and 
synovial fluid-derived mononuclear cells (SFMC) in different forms of arthritis and to correlate it with 
inflammatory mediators within intra-articular and circulatory compartments.  
Methods: Parallel PBMC and SFMC samples of patients with rheumatoid arthritis (RA; n=10) and psoriatic 
arthritis (PsA; n=10), and PBMC of healthy controls were cultured to assess osteoclastogenic potential by the 
number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts (OCs) and expression of OC-related 
genes (receptor activator of nuclear factor-κΒ (RANK), cFMS, and TRAP). Osteoclastogenesis was correlated 
with the arthritis-related inflammatory indicators in serum and synovial fluid (SF).  
Results: Number of OCs differentiated from PBMC was significantly higher in RA and PsA compared with 
control, with RA having more OCs compared with PsA. There was no difference in SFMC OC number 
between arthritic patients, but RANK expression in OCs differentiated from SFMC was higher in PsA 
compared with RA. SF of PsA patients more potently induced OC differentiation from control CD3
-
CD19
-
CD56
-
CD11b
+
CD115
+
 PBMC compared with RA, paralleled with higher RANK-ligand expression in PsA 
SFMC. Positive correlations of OC number with erythrocyte sedimentation rate, serum level of CCL2, and 
PBMC gene expression of interleukin-18 and Fas-ligand were observed.  
Conclusion: Osteoclastogenic potential is systemically enhanced in patients with RA, paralleled by 
disordered systemic and local expression of proinflammatory mediators, whereas PsA involves specific 
deregulation in RANKL/RANK axis. Our study reveals arthritis-specific mediators associated to the form of 
arthritis, indicating clinical relevance for diagnosis and treatment.  
 
Key words: rheumatoid arthritis, psoriatic arthritis, osteoclasts, cytokines, inflammation, bone loss, peripheral 
blood, synovial fluid
 3
Introduction 
Inflammatory arthritides comprise a heterogeneous group of joint disorders that are characterized by chronic 
inflammation, and intra-articular and generalized bone loss due to deregulated bone homeostasis; bone 
resorption by osteoclasts (OCs) and bone formation by osteoblasts [1]. Erosions of periarticular bone are the 
central feature of rheumatoid arthritis (RA) and also occur in spondyloarthritis (SpA) and erosive form of 
osteoarthritis [2].  
Development of bone erosions is critically dependent on OCs, capable of resorbing the mineralized matrix. 
OCs are multinuclear cells derived from mononuclear osteoclast progenitors (OCPs) of the monocyte-
macrophage lineage, which can be matured in vitro in the presence of macrophage colony-stimulating factor 
(M-CSF) and receptor activator of nuclear factor-κΒ ligand (RANKL) [1, 3]. OCPs are found in the 
peripheral blood (PB) and synovial tissue of patients with RA and SpA [4], mediating bone loss locally, in the 
form of bone erosions and joint osteolysis, and systemically, with the loss of bone mineral density (BMD) [5]. 
Under pathological conditions associated to arthritis, the process of osteoclastogenesis is markedly enhanced 
by various osteoclastogenic factors, including proinflammatory cytokines (interleukin (IL)-1, IL-6, IL-17, IL-
18, tumor necrosis factor α (TNF-α)), chemokines (such as CC-chemokine ligand 2 (CCL2), CCL3, CCL4), 
and apoptotic mediators (Fas-ligand (FasL), TNF-related apoptosis-inducing ligand, ligand for herpesvirus 
entry mediator) [6, 7]. It has been shown that even a small rise in the level of systemic inflammation can 
precipitate osteodestruction, leading to fractures and disabilities related to arthritis [2, 8].  
Although the enhanced osteoclastogenesis and osteoresorption have been confirmed in several forms of 
arthritis, relative contribution of systemic versus local changes to OC differentiation and activity has not been 
fully revealed. Moreover, discrimination criteria between forms of arthritis, regarding the mechanisms of 
osteoclastogenic response and key osteoclastogenic factors, have not been fully defined. The major aim of our 
study was to correlate the osteoclastogenic potential of peripheral blood mononuclear cells (PBMC) and 
synovial fluid-derived mononuclear cells (SFMC) with the parameters of systemic inflammation as well as 
circulating and intra-articular levels of proinflammatory/immunoregulatory mediators. In addition, we aimed 
to identify disease-specific factors that discriminate between control and arthritic subjects, and are best 
associated with osteoclastogenic potential, form of arthritis and disease activity. 
 4
Patients and Methods 
Patients  
A total of 20 patients with the following diseases: RA (n=10) and psoriatic arthritis (PsA) (n=10), admitted to 
the Rheumatology Department of the Clinical Hospital Center “Sisters of Mercy”, were included in the study 
after obtaining approval from the Ethics Committee and informed consent from patients (Table 1). The study 
was conducted in accordance with the Declaration of Helsinki. RA was diagnosed according to the revised 
American College of Rheumatology (ACR) criteria and PsA according to the Moll and Wright criteria. Paired 
synovial fluid (SF) and PB samples were obtained from RA and PsA groups, age and sex matched, which 
were further evaluated using the standard clinical variables (listed in Supplementary table 1) and laboratory 
parameters (C-reactive protein (CRP; mg/L), measured by standard nephelometric assay and erythrocyte 
sedimentation rate (ESR; mm/h), determined according to the Westergren method) (Table 1). PB samples of 
the age and sex matched control subjects (Ctrl) admitted due to non-inflammatory conditions, with normal 
values for inflammatory indicators (ESR and CRP; Table 1) and without history of autoimmune or joint 
diseases, were used for enzyme-linked immunosorbent assay (ELISA) (n=14) and OC cultures (n=8). Patients 
with RA and PsA significantly differ from controls in the systemic indicators of inflammation (ESR and CRP; 
Table 1). 
 
Osteoclast differentiation 
SF of arthritic patients was aspirated during therapeutic puncture of the affected knee. PB of arthritic patients 
and control subjects was obtained as a part of routine clinical assessment. PBMC and SFMC were separated, 
using Histopaque (Sigma-Aldrich, St. Louis, MO, USA).  
Isolated PBMC and SFMC were plated in α-minimal essential medium (α-MEM) supplemented with 10% 
fetal bovine serum (FBS). After 24 hours non-adherent cells were harvested and plated (3.5×10
5
 cells/well in 
96-well plate) over a glass coverslips in the presence of 40 ng/mL recombinant human (rh)M-CSF and 60 
ng/mL rhRANKL for additional 8 days [4]
 
. OCs were identified as tartrate-resistant acid phosphatase 
(TRAP)-positive cells with ≥2 nuclei/cell. OC differentiation was additionally confirmed by the expression of 
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OC-specific genes; receptor activator of nuclear factor-κΒ (RANK), macrophage colony-stimulating factor 
receptor (cFMS, CD115) and TRAP using quantitative (q)PCR.  
 
Gene expression analysis by qPCR 
Total RNA was extracted from PBMC/SFMC and OC cultures using TRIzol (Invitrogen by Life Technologies 
(LT), Grand Island, NY, USA), converted to complementary DNA and amplified in duplicates by qPCR in an 
ABI Prism 7500 Sequence Detection System (Applied Biosystems by LT). Gene expression of OC-specific 
genes (RANK, cFMS, TRAP) and proinflammatory/immunoregulatory mediators (TNF-α, IL-17, IL-18, FasL, 
RANKL) was assessed using TaqMan Assays (Applied Biosystems by LT) (Supplementary table 2) and 
presented as RNA relative quantity as previously described [7].  
 
ELISA 
The serum and SF concentrations of TNF-α (Quantikine High Sensitivity Immunoassay, R&D systems, 
Minneapolis, MN, USA), CCL2, IL-17, FasL (Quantikine Immunoassay, R&D systems), and IL-18 
(Quantikine Immunoassay, Medical & Biological Laboratories Co., LTD, Naka-ku, Nagoya, Japan) were 
determined in accord to the manufacturer instructions. Optical density was determined within 15 minutes on 
the microplate reader (Bio-Rad, Hercules, CA, USA) set to excitation wavelength at 450 nm (for CCL2, IL-
17, IL-18, and FasL) or 490 nm (for TNF-α). 
 
Cell sorting and co-culture 
PBMC of healthy volunteers (n=5) were pooled and labeled using the lymphoid (CD3/CD19/CD56) and 
myeloid markers (CD11b and CD14). OCPs were defined as CD3
-
CD19
-
CD56
-
CD11b
+
CD14
+
 cells and 
sorted using BD FACSAria I (BD Biosciences, Franklin Lakes, NJ, USA), with sorting purity >98%. Sorted 
cells (50000/cm
2
) were cultured in α-MEM/10% FBS supplemented with rhRANKL and rhM-CSF (20 ng/mL 
for both). Additionally, SF of individual RA and PsA patients was added in 40% volume proportion to assess 
its osteoclastogenic potential. 
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Statistical analysis  
Clinical data were presented as mean±standard deviation (SD). OC number and gene expression values were 
expressed as median with the interquartile range (IQR) and compared using non-parametric Kruskal-Wallis 
test followed by Mann-Whitney test with Bonferroni's correction for multiple testing. Correlations were 
assessed by Spearman's coefficient rho (ρ) with its 95% confidence interval (CI). Receiver-operating 
characteristic (ROC) curve analysis was presented as area under the curve (AUC) with its 95% CI, and used 
to discriminate between arthritic and control group. Statistical analysis was performed using the MedCalc 
software package (Mariakerke, Belgium). For all experiments, α-level was set at 0.05. 
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Results 
Enhanced osteoclastogenic potential in atrhritic patients 
Number of TRAP-positive OCs differentiated from PBMC of patients with RA and PsA was significantly 
higher compared with control (RA vs ctrl p=0.008, PsA vs ctrl p<0.001; Fig. 1a and b), with the most 
prominent osteoclastogenic potential in RA (RA vs PsA p=0.043; Fig. 1b). In parallel, expression of RANK 
and TRAP was higher in freshly isolated PBMC (day 0) from RA and PsA patients, but reached the statistical 
significance only for RANK in PsA compared with control (p=0.003; Fig. 1c).  
In contrast, there was no significant difference in the number of TRAP-positive OCs differentiated from 
SFMC (Fig. 1a and b). Nevertheless, SFMC derived OCs from PsA patients were morphologically different 
(larger with more nuclei/cell; Fig. 1a). Gene expression for RANK and TRAP in freshly isolated SFMC (day 0) 
of PsA patients was higher compared with RA, but did not reach statistical significance (Fig. 1c).  
OC differentiation was confirmed by the increase in the expression of OC-specific genes with the duration of 
osteoclastogenic cultures from arthritic patients (comparison of day 0 (white bars) and day 10 (grey bars); Fig. 
1c), particularly for RANK and TRAP. We found more than 3-fold higher RANK expression at the OC-culture 
end-point for PBMC (day 10) of RA compared with PsA (p=0.004; Fig. 1c), and more than 5-fold higher 
RANK expression for SFMC (day 10) of PsA compared with RA (p=0.048; Fig. 1c).  
 
Association of systemic and intra-articular osteoclastogenic potential in arthritis 
To determine the profile of soluble systemic and local osteoclastogenic factors, we selected TNF-α, CCL2, 
IL-17 and IL-18, and assessed them in PB and SF at both protein and gene expression levels (Fig. 2a and b). 
Overall, concentrations of selected inflammatory mediators were higher in SF than in serum, with RA SF 
having the peak values for CCL2, TNF-α and IL-17 (Fig. 2a).  
Serum concentration of CCL2 was significantly higher in RA patients compared with control (p=0.016; Fig. 
2a) and positively correlated with the number of OCs derived from PBMC (p=0.036; Fig. 3). For TNF-α, we 
could not find statistically significant difference at the protein or gene expression level between groups, 
although the values were highest for SF of RA patients (Fig. 2a). Serum levels of IL-17 in patients with PsA 
were elevated compared with controls (PsA vs ctrl, p=0.013) as well as in SF of RA patients compared with 
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PsA (p=0.054) (Fig. 2a). Gene expression of IL-18 in PBMC was significantly higher in all forms of arthritis 
compared with controls (RA vs ctrl, p<0.001; PsA vs ctrl, p<0.001; Fig. 2b). At the protein level, IL-18 was 
the most prominent in both serum and SF of RA patients, but the difference was not statistically significant 
(Fig. 2a). Furthermore, statistically significant positive correlation was observed between the IL-18 PBMC 
gene expression and PBMC OC number (p=0.049; Fig. 3).  
In addition, we found increased gene expression of FasL in PBMC of patients with PsA compared with 
control (p=0.003; Fig. 2b) as well as positive correlation between both soluble FasL concentration in sera 
(ρ=0.412, 95% CI 0.067 to 0.669, p=0.024; not shown) and FasL PBMC gene expression (p=0.017; Fig. 3) 
with the number of PBMC derived OCs.  
Finally, we functionally tested the osteoclastogenic potential of SF by co-culture of sorted OCPs (defined as 
CD3
-
CD19
-
CD56
-
CD11b
+
CD14
+
 population) in osteoclastogenic media containing 40% volume proportion of 
the individual SF from RA or PsA patients (Fig. 4a). In that model we confirmed significantly more efficient 
osteoclastogenesis in co-cultures treated with PsA SF compared with RA SF (p=0.040; Fig. 4b). Moreover, 
PsA patients had significantly higher RANKL expression in SFMC (p=0.042; Fig. 4c) but similar in PBMC 
compared with RA patients (Fig. 4c).  
 
Correlation between osteoclastogenic potential and indicators of inflammation  
ESR, indicator of chronic systemic inflammation, positively correlated with the number of differentiated OCs 
from PBMC (p=0.023; Fig. 3). However, we could not confirm significant correlations with osteoclastogenic 
potential for other clinical variables, probably due to the small group size. Furthermore, we subdivided the 
patients regarding the sulphasalazine (SSZ) treatment, used as a disease-modifying antirheumatic drug, and 
found that they had significantly reduced levels of FasL (p=0.013, respectively, Mann-Whitney test) in SF 
(n=10) compared with patients not receiving SSZ (n=10). 
ROC curve analysis revealed that the control and patient groups could be distinguished based on the number 
of ex vivo matured OCs (AUC=0.921, 95% CI 0.750 to 0.987, p<0.001), serum level of CCL2 (AUC=0.697, 
95% CI 0.499 to 0.852, p=0.045), and PBMC gene expression of IL-18 (AUC=1.000, 95% CI 0.871 to 1.000, 
p<0.001) and FasL (AUC=0.793, 95% CI 0.594 to 0.923, p=0.001) (Fig. 5).  
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In contrast, there was no significant correlation between the SF osteoclastogenic mediators or circulatory 
indicators of inflammation and the number of differentiated OCs from SFMC, suggesting that SF represents 
the specific compartment that is locally regulated by infiltrating immune cells. Nevertheless, we found the 
significant positive correlation between CCL2 gene expression in SFMC osteoclastogenic culture end-point 
(day 10) and number of differentiated OCs (ρ=0.546, 95% CI 0.0697 to 0.820, p=0.034), indicating that intra-
articular OCs may contribute to the enhanced osteoclastogenic potential within the affected joints.
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Discussion 
Our study confirmed systemic enhancement of osteoclastogenesis in arthritis, particularly RA. Increased 
osteoclastogenic potential of PBMC positively correlated with proinflammatory mediators in circulation and 
inflammation intensity, confirming that inflammation is a trigger for enhanced OC activity. OCPs are 
contained among both PBMC and SFMC, but not with the same frequency in RA and PsA, and even within 
the PBMC and SFMC of the same patient. We concluded that circulatory and intra-articular compartments 
possess distinct profiles of osteoclastogenic factors and OC-inducing capacity.  
Higher number of OCs differentiated from PBMC of RA and PsA patients compared with controls. Moreover, 
more differentiated OCs and induced RANK expression were found in RA compared with PsA patients, 
reflecting high osteoclastogenic potential of circulatory compartment. Human OCPs are present at low 
frequency in normal PB within the monocyte population [1], and increase in number and osteoclastogenic 
potential in arthritis [9, 10], but this is the first study to include control subjects and patients suffering from 
different forms of arthritis, using paired PBMC and SFMC arthritic samples for osteoclastogenic assay.  
In addition to the systemic changes, inflamed joints are marked with severe lymphocyte infiltration especially 
in RA, with the predominance of T lymphocytes within the SF [11]. Therefore, by plating the same number of 
SFMC for osteoclastogenic cultures as for PBMC, we included lower number of OCPs, giving us the overall 
lower number of ex vivo matured OCs and no difference between RA and PsA. Bone loss in RA and PsA 
occurs to the similar extent, either locally in the peripheral joints, or systemically with loss of BMD [2, 12]. 
However, in the functional assay SF of PsA patients showed more potent OC-inducing activity compared with 
RA, paralleled by higher RANKL and RANK expression, corroborating that PsA involves specific change in 
RANKL/RANK axis [5]. Ritchlin et al demonstrated intense RANKL expression throughout the synovial 
lining layer, implicating enhanced RANKL-mediated osteoclastogenesis in PsA [10]. 
Proinflammatory profile in our patients included the highest level of CCL2 in RA patients, and positive 
correlation with the number of PBMC derived OCs. Also, CCL2 was highly induced with OC maturation, 
with the positive correlation between OC CCL2 expression and the number of OCs differentiated from 
SFMC. It has been shown, using CCL2-deficient mice and human PBMC, that CCL2 regulates OC 
differentiation in an autocrine/paracrine manner and that OCPs express CCL2 receptors, CCR2 and CCR4 
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[13, 14]. Kim et al proposed that RANKL-stimulated OC-lineage cells send a chemokine signal to attract 
OCPs to the site of RANKL signaling, resulting in cell fusion to multinuclear OCs [15].  
Association of proinflammatory factors with osteoclastogenic potential confirmed that they play a role not 
only in creating inflammatory environment but also in inducing osteoresorption. IL-17 and IL-18 were both 
elevated systemically and, together with TNF-α, the most prominent in SF of RA patients. TNF-α was not 
increased in serum, but overall concentrations in all groups were very low. TNF-α and IL-17 are able to 
induce RANK expression on human OCPs and OC differentiation [16, 17], and are substantial factors in 
inflammation-mediated bone destruction [18, 19]. Results for IL-18 effects on osteoclastogenesis are still 
controversial, suggesting both anti-osteoclastogenic [20] and pro-osteoclastogenic effects, via induction of 
TNF and RANKL in synovial T lymphocytes and fibroblast-like synoviocytes [21, 22]. Intra-articular 
osteoclastogenic milieu, observed in our study, may support OCPs not only in SF but also on bone surfaces, 
causing periarticular bone erosions [10]. Moreover, we believe that lack of correlation between 
proinflammatory mediators and number of OCs differentiated from SFMC could be explained by the fact that 
those mediators act on the pannus-bone interface and enhance OCPs attachment to the resorption lacunas 
where they are not available for harvesting by SF aspiration. 
Besides inflammatory mediators, we found increased expression of FasL in PBMC of PsA patients and a 
positive correlation with the number of PBMC-derived OCs. A disease-modifying drug SSZ was able to 
reduce FasL in SF of treated patients. Although Fas/Fas ligand system is involved in the regulation of bone 
homeostasis, the role in arthritis is still controversial [7, 23, 24]. Resident synoviocytes and infiltrating 
immune cells are resistant to FasL-mediated apoptosis, contributing to joint lesions [24]. Increased expression 
could represent a compensatory mechanism to induce apoptosis of autoreactive T lymphocytes in autoimmune 
conditions. 
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Conclusions 
In conclusion, our study revealed disease-specific changes despite high heterogeneity of SF milieu between 
patients, reflecting chronic nature of the disease and great variability in SF content [11]. In particular, RA 
patients have the highest values of inflammatory mediators in both serum and SF, implicating alternate 
osteoclastogenic pathways independent of RANKL and TNF-α [25].  On the other hand, PsA involves 
specific increase in RANKL/RANK expression in synovial compartment, creating potent osteoclastogenic 
environment in the affected joints. Our findings indicate arthritis-specific mediators associated to the form of 
arthritis, which may be clinically relevant for the development of diagnostic or therapeutic strategies targeting 
proinflammatory and osteoclastogenic effects of arthritis. 
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Table 1. Selected demographic and clinical characteristics of control subjects and patients with rheumatoid 
arthritis (RA) and psoriatic arthritis (PsA)  
 
Characteristic
a
 Control RA PsA 
Number of subjects 14
b
 10
c 
10
c 
Male/Female 5/9 3/7 3/7 
Age, years 59.7±14.7 55.8±9.1 48.3±11.5 
Disease duration, years NA 12.1±12.6 11.2±10.2 
ESR, mm/hour 9.0±4.0 51.4±37.8 32.7±20.5 
CRP, mg/liter 2.7±0.8 57.1±23.9 38.3±21.2 
Swollen joint count (28-joint score) NA 6.4±4.1 4.8±4.2 
Tender joint count (28-joint score) NA 13.3±7.5 9.9±7.4 
DAS28 (0-10) NA 6.0±0.9 5.1±1.3 
BASDAI (0-10) NA NA 3.3±3.0 
MASES (0-13) NA NA 4.2±4.6 
Larsen score for RA (0-4); Radiological 
score of sacroileitis for PsA (0-4) NA 2.7±0.5 2.8±0.4 
NSAIDs NA 7/10 6/10 
DMARDs NA 5/10 5/10 
Corticosteroids NA 1/10 2/10 
a
 Values are presented as mean ± standard deviation. ESR, erythrocyte sedimentation rate; CRP, C-reactive 
protein; DAS28, Disease Activity Score including a 28-joint count; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NSAIDs, non-steroid 
anti-inflammatory drugs; DMARDs, disease-modifying antirheumatic drugs; NA, not applicable. 
b
 Sera of 14 
control patients were analyzed by ELISA, whereas 8 PBMC control samples were subjected to 
osteoclastogenic assay. 
c
 Patients with RA and PsA were not treated with biological agents. 
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Figure legends 
 
Fig. 1 Osteoclastogenic cultures of peripheral blood mononuclear cells (PBMC) and synovial fluid-derived 
mononuclear cells (SFMC) from arthritic patients  
(a) Osteoclasts (OCs) were identified as TRAP-positive cells with ≥2 nuclei/cell (representative cultures). (b) 
Number of TRAP-positive OCs/well differentiated from control subjects (PBMC), and arthritic patients with 
RA and PsA (PBMC and SFMC), presented as median (IQR). (c) Expression of OC-specific genes in PBMC 
(PB) and SFMC (SF) at culture days 0 and 10, presented as RNA relative quantity (median (IQR)). Group-to-
group comparisons were performed using Mann-Whitney test, p values ≤0.05 are shown. RANK, receptor 
activator of nuclear factor-κΒ; cFMS, macrophage colony-stimulating factor receptor; TRAP, tartrate-resistant 
acid phosphatase. 
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Fig. 2 Proinflammatory/immunoregulatory mediators in circulatory and intra-articular compartments of 
arthritic patients  
(a) Mediators were analyzed in serum and synovial fluid (SF) at the protein level by ELISA, and (b) in 
peripheral blood mononuclear cells (PBMC) and synovial fluid-derived mononuclear cells (SFMC) at the 
gene expression level by qPCR. Values are presented as RNA relative quantity (median (IQR)) for each 
group. Group-to-group comparisons were performed using Mann-Whitney test, p values ≤0.05 are shown. 
CCL2, CC chemokine ligand 2; TNF-α, tumor necrosis factor α; FasL, Fas ligand; IL, interleukin.  
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Fig. 3 Correlation between osteoclastogenic potential and inflammation indicators  
Significant correlations were found for the number of osteoclasts (OCs) differentiated from peripheral blood 
mononuclear cells (PBMC) with erythrocyte sedimentation rate (ESR), as indicator of systemic inflammation, 
and osteoclastogenic mediators: serum concentration of CC chemokine ligand 2 (CCL2) and PBMC gene 
expression of interleukin-18 (IL-18) and Fas ligand (FasL). Values were correlated using rank correlation and 
Spearman´s coefficient ρ (95% confidence interval (CI) for ρ), p values ≤0.05 are shown.  
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Fig. 4 Comparison of synovial fluid (SF) osteoclastogenic effect from patients with rheumatoid arthritis (RA) 
and psoriatic arthritis (PsA)  
(a) Osteoclastogenic effect of SF in a co-culture model of sorted osteoclasts (OC) progenitors (CD3
-
CD19
-
CD56
-
CD11b
+
CD14
+
cells from control peripheral blood mononuclear cells (PBMC) samples (n=5)), 
differentiated (50000 cells/cm
2
) with receptor activator of nuclear factor κΒ ligand (RANKL) and 
macrophage colony-stimulating factor (M-CSF), and individual SFs from RA or PsA patients (in 40% volume 
proportion). (b) Number of TRAP-positive OCs/well differentiated in the co-culture model of sorted OC 
progenitors and SFs from RA or PsA patients. Dashed line presents number of OCs/well differentiated in 
control (Ctrl) cultures that were not treated with arthritic SF. (c) Gene expression of RANKL in PBMC and 
synovial fluid-derived mononuclear cells (SFMC) of patients with RA and PsA. Values are presented as 
median (IQR). Group-to-group comparisons were performed using Mann-Whitney test, p values ≤0.05 are 
shown. TRAP, tartrate-resistant acid phosphatase. 
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Fig. 5 Discriminatory ability of osteoclast (OC) differentiation potential and proinflammatory mediators 
between arthritic and control samples 
Receiver operating characteristic (ROC) curves for the number of OCs differentiated from peripheral blood 
mononuclear cells (PBMC), serum concentration of CC chemokine ligand 2 (CCL2), and PBMC gene 
expression of interleukin-18 (IL-18) and Fas ligand (FasL). Diagnostic efficacy for those values was assessed 
using the sensitivity and specificity at a cut-off point. ROC curve analyses, p values (for area under curve = 
0.5) ≤0.05 are shown. 
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Supplementary table 1. Clinical variables recorded in patients with rheumatoid arthritis (RA) and psoriatic arthritis 
(PsA)  
 
Variable RA PsA 
duration of the disease and symptoms (years) + + 
patient assessment of pain, fatigue and disease activity (VAS) + + 
patient assessment of the duration (min) and intensity of morning stiffness (VAS) + + 
patient assessment of spinal pain (VAS) NA + 
patient assessment of enthesial pain (VAS) NA + 
physician assessment of disease activity (VAS) + + 
laboratory variables: erythrocite sedimentation rate (mm/h), C-reactive protein (mg/L), 
HLA genotyping 
+ + 
joint scores for tenderness and swelling (28-joint score)  + + 
DAS28 (0-10) + + 
BASDAI (0-10) NA + 
MASES (0-13)  NA + 
Larsen score (0-4) + NA 
radiological score of sacroileitis (0-4) NA + 
radiological assessment of spondylitis for PsA (yes/no) NA + 
radiological assessment of erosive changes of wrists, small joints of the hand and foot 
(yes/no) 
NA + 
dactylitis, psoriasis of the nails and skin (yes/no) NA + 
a
 VAS, visual analog scale; DAS28, Disease activity score including a 28-joint count; BASDAI, Bath ankylosing 
spondylitis disease activity index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; radiological score of 
sacroileitis (Jajic I. Ann Rheum Dis 1968); NA, not applicable. 
Supplementary table 2. TaqMan assays used for qPCR analysis 
 
Gene
a
 Gene symbol Assay ID 
RANK TNFRSF11A Hs00187189_m1 
cFMS CSF1R Hs00234622_m1 
TRAP ACP5 Hs00356261_m1 
TNF-a TNF Hs99999043_m1 
CCL2 CCL2 Hs00234140_m1 
IL-17 IL17A Hs00174383_m1 
IL-18 IL18 Hs00155517_m1 
FasL FASLG Hs00181255_m1 
RANKL TNFSF11 Hs00243522_m1 
GAPDH GAPDH Hs99999905_ml 
a
Assays used for qPCR analysis were commercially available and used in accord to the manufacturer recommendation 
(Applied Biosystems). 
 
